Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Enhertu Earns FDA’s Priority Tag for Gastric Cancer, Decision Due in Q1 2021
Daiichi Sankyo and AstraZeneca said on October 28 that the US FDA has accepted for priority review their antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) for an additional indication of certain patients with gastric cancer.Their application seeks the drug’s label…
To read the full story
Related Article
- Enhertu Gets FDA Nod for Gastric Cancer, 2nd Indication in US
January 19, 2021
- Enhertu Gets US FDA’s Orphan Status for Gastric Cancer
May 25, 2020
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





